ProMIS Neurosciences Inc. (PMN) company profile
Close on Nov 17, 2026Market cap $28.79MP/E –Yield –
About ProMIS Neurosciences
Pharmaceutical Preparations, SIC 2834
ProMIS Neurosciences develops therapeutic antibodies and vaccines targeting neurodegenerative and protein-misfolding disorders. Using its proprietary EpiSelect computational platform, the company predicts conformational disease-specific epitopes to generate humanized monoclonal antibodies and intrabodies that selectively neutralize neurotoxic misfolded proteins without disrupting healthy counterparts. Its pipeline includes PMN310, an antibody candidate undergoing clinical evaluation for Alzheimer’s disease designed to avoid monomer distraction and vascular plaque binding, alongside preclinical programs such as PMN267 for amyotrophic lateral sclerosis and frontotemporal lobar degeneration, and therapeutic candidates directed against alpha-synuclein for synucleinopathies.
The company conducts clinical development activities across multiple regions, having completed patient enrollment for its Phase 1b PRECISE-AD clinical study across 21 active clinical trial sites located in the United States. Preclinical research models and collaborative studies for its drug development programs have taken place in France, Belgium, and the United States. The company acquired technology licensing rights from the University of British Columbia, while the text does not disclose corporate headquarters or commercial facilities.
Summary of the business section of ProMIS Neurosciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- ProMIS Neurosciences Inc.
- Headquarters
- Toronto, A6
- Address
- Suite 200, 1920 Yonge Street M4S 3E2
- Phone
- (416) 847-6898
- Website
- promisneurosciences.com
- Employees
- 30,000, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Z4
- Fiscal year ends
- December 31
- Auditor
- Baker Tilly US, LLP, Tewksbury, Massachusetts
Stock & identifiers
- Ticker
- PMN
- Exchange
- Nasdaq
- IPO date
- Jan 10, 2007
- Shares outstanding
- 9M, Aug 13, 2026
- Public float
- $29.70M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Stock splits
- 1-for-25 reverse, Nov 28, 2025; 1-for-60 reverse, Jun 28, 2022
- SEC CIK
- 1374339
- CUSIP
- 74346M505
- ISIN
- CA74346M5054
- FIGI
- BBG000R0MF47
- Share class FIGI
- BBG001SMDG62
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Neil Cashman | Chief Scientific Officer, Director | 19,318 |
| Neil K. Warma | Chief Executive Officer, Director | 6,183 |
| Ivana Rubino | Chief Commercial Officer | – |
| Johanne Kaplan | Chief Development Officer | 6,221 |
| Max A. Milbury | Principal Accounting Officer | 8,409 |
| Larry Douglas Altstiel | Chief Medical Officer | – |
| Eugene Williams | Director | 40,213 |
| Josh Mandel-Brehm | Director | – |
| Madge K. Shafmaster | Director | 208,333 |
| Slanix Paul Alex | Director | 6,058,738 |
| William W. Wyman | Director | 62,937 |
| Patrick D. Kirwin | Director | 10,093 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Option awards | Total | vs. prior year |
|---|---|---|---|---|---|
| Neil Warma CEO | $500.00K | $104.00K | $226.17K | $830.17K | -64% |
| Johanne Kaplan Chief Development Officer | $386.67K | $133.00K | $62.20K | $581.86K | – |
| Larry Altstiel Chief Medical Officer | $425.00K | $57.00K | $62.20K | $544.20K | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“It is estimated there are currently 30,000 people in the United States and 450,000 people worldwide, suffering from ALS, with approximately 5,000 new cases arising in the United States annually.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 8, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jul 5, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jul 29, 2022 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Jun 22, 2022 | Spin-off | Registration as a new public company (Form 10), e.g. spin-off |
| Nov 3, 2014 | Name change | Name changed from AMORFIX LIFE SCIENCES LTD to ProMIS Neurosciences Inc. |
See a number that looks wrong?